Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Cantor Fitzgerald
Colorcon
US Department of Justice
Citi
Julphar
Cerilliant
Johnson and Johnson
Baxter

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VINFLUNINE

« Back to Dashboard

Clinical Trials for Vinflunine

Trial ID Title Status Sponsor Phase Summary
NCT00101608 Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed Pierre Fabre Medicament Phase 2 The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium. The safety of this treatment will also be studied.
NCT00101608 Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed Bristol-Myers Squibb Phase 2 The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium. The safety of this treatment will also be studied.
NCT00251446 A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer Completed Bristol-Myers Squibb Phase 2 This is a Phase II, single-arm study in patients with stage IIIB (with malignant pleural effusion) and IV NSCLC who have been previously treated with a platinum-based doublet. Each cycle will be 21 days. On Day 1 of each cycle, patients will receive vinflunine 320 mg/m2 as a 20-minute IV infusion. Patients will continue to receive study treatment until disease progression or unacceptable toxicity. Patients will be evaluated every 2 cycles for response using RECIST criteria.
NCT00251446 A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer Completed Veeda Oncology Phase 2 This is a Phase II, single-arm study in patients with stage IIIB (with malignant pleural effusion) and IV NSCLC who have been previously treated with a platinum-based doublet. Each cycle will be 21 days. On Day 1 of each cycle, patients will receive vinflunine 320 mg/m2 as a 20-minute IV infusion. Patients will continue to receive study treatment until disease progression or unacceptable toxicity. Patients will be evaluated every 2 cycles for response using RECIST criteria.
NCT00284154 Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed Bristol-Myers Squibb Phase 2 This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.
NCT00284154 Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed SCRI Development Innovations, LLC Phase 2 This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vinflunine

Condition Name

Condition Name for
Intervention Trials
Bladder Cancer 8
Breast Cancer 4
Urothelial Cancer 4
Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Urinary Bladder Neoplasms 9
Carcinoma, Transitional Cell 9
Carcinoma 9
Breast Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vinflunine

Trials by Country

Trials by Country for
Location Trials
United States 138
Spain 26
Canada 22
Italy 22
United Kingdom 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Florida 9
Tennessee 7
Texas 7
South Carolina 6
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vinflunine

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 10
Phase 2/Phase 3 4
Phase 2 11
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 16
Recruiting 8
Active, not recruiting 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vinflunine

Sponsor Name

Sponsor Name for
Sponsor Trials
Bristol-Myers Squibb 11
Pierre Fabre Medicament 8
National Cancer Institute (NCI) 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 30
Other 17
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Deloitte
US Army
Baxter
Fish and Richardson
Johnson and Johnson
Chubb
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.